Storia in 2 fonti

Parabilis Medicines 33.5M share IPO priced at $20.00

The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeSc...

Raccontata da

markets.businessinsider.com

cryptobriefing.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

markets.businessinsider.comStai leggendo2 g fa

Parabilis Medicines 33.5M share IPO priced at $20.00

The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeSc...

originale

cryptobriefing.com1 g fa

Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range

Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 million Regeneron private placement.

Leggi questa versione → originale

Timeline cronologica

mercoledì 10 giugno 2026·markets.businessinsider.com
ERock 27.91M share IPO priced at $21.50
The deal priced at midpoint of $20.00-$23.00 target range. Morgan Stanley, JPMorgan, Barclays and BofA are acting as joint book running manager...
mercoledì 10 giugno 2026·markets.businessinsider.com
Parabilis Medicines 33.5M share IPO priced at $20.00
The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeSc...

Parabilis Medicines 33.5M share IPO priced at $20.00

Confronto fonti

Parabilis Medicines 33.5M share IPO priced at $20.00

Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range

Timeline cronologica

ERock 27.91M share IPO priced at $21.50

Parabilis Medicines 33.5M share IPO priced at $20.00

Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range

PureCycle Technologies $145M Spot Secondary; price range $8.21-$8.71

Humacyte TBA Spot Secondary; price range $1.05-$1.15